Chimeric antigen receptor T-cell therapies have demonstrated limited antitumor activity in glioblastoma. Although the therapies have been tolerable, response rates have been low and responses lack durability.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
